SCHEMBL7184698

SCHEMBL7184698

CCOc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(OCC)c1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
KMT2A Q03164 1/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
TP53 P04637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
PDK2 Q15119 2/20 0.37
MAOB P27338 2/20 0.37
MAOA P21397 1/20 0.37
AR P10275 1/20 0.37
HPGD P15428 2/20 0.36
NPC1 O15118 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7184703 0.98 KDM4E (0.42) KDM4EKMT2AKCNK3KCNK9RXRA
SCHEMBL7182872 0.89 THRA (0.41) KMT2AMRGPRX4PDK2
SCHEMBL7177770 0.89 KMT2A (0.40) KMT2AMRGPRX4L3MBTL1CYP1A1CYP1B1
SCHEMBL7189202 0.88 KMT2A (0.42) KDM4EKMT2AKCNK3KCNK9RXRA
SCHEMBL7188859 0.88 LMNA (0.41) KDM4EKMT2AKCNK3KCNK9MRGPRX4
SCHEMBL7181374 0.87 THRA (0.44) MRGPRX4PDK2
Lithium SCHEMBL7177779 0.86 KMT2A (0.40) KMT2AMRGPRX4L3MBTL1CYP1A1CYP1B1
Lithium SCHEMBL7182881 0.86 THRB (0.41) KMT2AMRGPRX4PDK2
SCHEMBL7179765 0.86 THRA (0.46) PDK2
SCHEMBL7180865 0.86 KCNK3 (0.43) KDM4EKMT2AKCNK3KCNK9RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KDM4E 3226/4885KMT2A 1586/4885KCNK3 351/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KDM4E 2651/4885KMT2A 956/4885KCNK3 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.